Exchange: NASDAQ·Updated 07:47 PM EST

OTLK News

News
all
press releases
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
(RTTNews) - On Friday, Outlook Therapeutics (OTLK), a biopharmaceutical company developing and commercializing LYTENAVA for retinal diseases, announced Greg DiPasquale as Chief Commercial Officer...
Nasdaq News: Markets
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
(RTTNews) - On Friday, Outlook Therapeutics (OTLK), a biopharmaceutical company developing and commercializing LYTENAVA for retinal diseases, announced Greg DiPasquale as Chief Commercial Officer...
Nasdaq News: Markets
More News
Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
Zacks
Outlook Therapeutics (NASDAQ:OTLK) released third-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-timeread more...
Benzinga
Outlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.read more...
Benzinga
Zealand Pharma AS (ZLDPF) delivered earnings and revenue surprises of +2,150.00% and +756.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Outlook Therapeutics is looking to sell about 55.6 million common shares, accompanied by warrants, at a 10% discount over the stock’s closing price on Wednesday.
Stocktwits
Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.
Zacks
IRHYTHM HLDGS (IRTC) delivered earnings and revenue surprises of +5,900.00% and +2.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks

Advertisement|Remove ads.